Patents by Inventor Lisa Cavacini
Lisa Cavacini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8252894Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: May 9, 2011Date of Patent: August 28, 2012Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120208270Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 16, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120201833Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 9, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120201834Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 9, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120196359Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 2, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Patent number: 8084595Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: June 28, 2010Date of Patent: December 27, 2011Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20110274700Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20110002932Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: June 28, 2010Publication date: January 6, 2011Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Patent number: 7786255Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: April 21, 2005Date of Patent: August 31, 2010Assignees: The Bringham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Patent number: 7230087Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: June 29, 2005Date of Patent: June 12, 2007Assignees: Beth Israel Deaconess Medical Center, Inc., Brigham & Women's Hospital, Inc.Inventors: Gerald B. Pier, Michael J. Preston, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20060235206Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: June 21, 2006Publication date: October 19, 2006Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald Pier, Michael Preston, Lisa Cavacini, Marshall Posner
-
Patent number: 7119172Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: May 16, 2003Date of Patent: October 10, 2006Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Michael J. Preston, Lisa Cavacini, Marshall Posner
-
Publication number: 20060153856Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: June 29, 2005Publication date: July 13, 2006Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald Pier, Michael Preston, Lisa Cavacini, Marshall Posner
-
Publication number: 20060115486Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: April 21, 2005Publication date: June 1, 2006Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald Pier, Casie Kelly-Quintos, Lisa Cavacini, Marshall Posner
-
Patent number: 6962813Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: May 21, 2002Date of Patent: November 8, 2005Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Michael J. Preston, Lisa Cavacini, Marshall Posner
-
Publication number: 20040091494Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: May 16, 2003Publication date: May 13, 2004Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Michael J. Preston, Lisa Cavacini, Marshall Posner
-
Publication number: 20030124631Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: May 21, 2002Publication date: July 3, 2003Inventors: Gerald B. Pier, Michael J. Preston, Lisa Cavacini, Marshall Posner